Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes

被引：0
|
作者：
Junko Oya
Tomoko Nakagami
Yukiko Hasegawa
Yuichiro Kondo
Aki Katamine
Mika Shimizu
Ryo Kubota
Rika Suda
Tetsuya Babazono
机构：
[1] Tokyo Women’s Medical University School of Medicine,Division of Diabetology and Metabolism, Department of Internal Medicine
来源：
Diabetology International | 2024年 / 15卷
关键词：
Type 2 diabetes; Insulin degludec/liraglutide; Insulin degludec/insulin aspart; HbA1c;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 243
页数：6
相关论文
共 50 条
  • [41] Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects
    Haahr, Hanne
    Sasaki, Tomio
    Bardtrum, Lars
    Ikushima, Ippei
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 574 - 580
  • [42] Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial
    Kaku, Kohei
    Araki, Eiichi
    Tanizawa, Yukio
    Agner, Bue Ross
    Nishida, Tomoyuki
    Ranthe, Mattis
    Inagaki, Nobuya
    DIABETES OBESITY & METABOLISM, 2019, 21 (12): : 2674 - 2683
  • [43] Comparison of Insulin Glargine with Insulin Degludec in Type 1 Diabetes Patients
    Kuroda, Akio
    Tsuruo, Miho
    Takeshi, Kondo
    Aki, Nanako
    Oguro, Yukari
    Endo, Itsuro
    Aihara, Ken-ichi
    Tamaki, Motoyuki
    Matsumoto, Toshio
    Matsuhisa, Munehide
    DIABETES, 2014, 63 : A232 - A232
  • [44] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
    Marc Evans
    Barrie Chubb
    Jens Gundgaard
    Diabetes Therapy, 2017, 8 : 275 - 291
  • [45] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
    Evans, Marc
    Chubb, Barrie
    Gundgaard, Jens
    DIABETES THERAPY, 2017, 8 (02) : 275 - 291
  • [46] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
    Sellam, Y.
    Malek, R.
    Semrouni, M.
    Belhadj, M.
    Zekri, S.
    Brouri, M.
    Arbouche, Z.
    Nouri, N.
    VALUE IN HEALTH, 2020, 23 : S511 - S511
  • [47] Low Fasting Glucose and Insulin Deficiency Were Related with Superiority of Insulin Degludec/Aspart Compared with Basal Insulin in Patients with Type 2 Diabetes
    Jang, Han Na
    Yang, Ye Seul
    Oh, Tae Jung
    Koo, Bo Kyung
    Lee, Seongok
    Jung, Hye Seung
    DIABETES, 2021, 70
  • [48] The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
    Glastras, Sarah J.
    Cohen, Neale
    Dover, Thomas
    Kilov, Gary
    MacIsaac, Richard J.
    McGill, Margaret
    Fulcher, Greg R.
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [49] SAFETY AND EFFICACY OF INSULIN GLARGINE/LIXISENATIDE AND INSULIN DEGLUDEC/INSULIN ASPART IN TYPE 2 DIABETES PATIENTS NOT CONTROLLED ON BASAL INSULIN: A NETWORK META-ANALYSIS
    Jammah, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A185 - A186
  • [50] The Study on the Clinical Efficacy of Insulin Degludec/Insulin Aspart (IDegAsp)
    Kusama, Minoru
    DIABETES, 2018, 67
12345